Japanese Journal of Ophthalmology

, Volume 52, Issue 4, pp 331–333

Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)

Brief Communication

Abstract

Background

Imatinib is effective for a variety of hematologic and nonhematologic malignancies. Well-known ocular side effects are periorbital edema, epiphora, extraocular muscle palsy, and blepharoconjunctivitis. However, optic disc edema has not been reported as a complication of imatinib mesylate. Herein, we describe a patient with chronic myeloid leukemia (CML) who developed optic disc edema during treatment with imatinib.

Case

A 14-year-old Korean girl was referred to ophthalmology for a 3-week history of photopsia in both eyes. She had started taking imatinib daily 2 months previously for CML. At the initial exam, slit lamp showed optic disc edema in both eyes, even though visual acuity was 20/20 and other optic nerve function evaluations were within normal limits. We recommended to the oncologist discontinuation of the imatinib treatment.

Observations

When the patient was followed for 1 week after stopping imatinib treatment, the frequency of photopsia decreased and the optic disc edema improved. Because a second examination 3 weeks after discontinuation of imatinib revealed much improved optic disc edema, she restarted the imatinib treatment. No ocular side effects have been noted so far.

Conclusions

Optic disc edema should be considered one of the complications associated with imatinib. We propose discontinuation of the treatment for a short period when optic disc edema occurs.

Key Words

imatinib mesylate optic disc edema 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.PubMedCrossRefGoogle Scholar
  2. 2.
    Pietras K, Östman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929–2934.PubMedGoogle Scholar
  3. 3.
    Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side effects in chronic myeloid leukemia patients treated with associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003;19:371–375.PubMedCrossRefGoogle Scholar
  4. 4.
    Kusumi E, Arakawa A, Kami M, et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004;18:1138–1139.PubMedCrossRefGoogle Scholar
  5. 5.
    Babu KG, Attili VSS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 2007;27:43–44.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society (JOS) 2008

Authors and Affiliations

  1. 1.Department of OphthalmologyHallym University Sacred Heart HospitalAnyangKorea
  2. 2.Department of PediatricsHallym University Sacred Heart HospitalAnyangKorea
  3. 3.Department of OphthalmologyHallym University Sacred Heart HospitalAnyang, Gyeonggi-doKorea

Personalised recommendations